IDEXX Grew 10% While the Waiting Room Shrank

The premium, not the traffic

For two years IDEXX told the same story about the same number. U.S. same-store clinical visits were down, wellness visits were down harder, and management attributed it to a pressured consumer. On the February call the framing was resignation dressed as patience — “We have seen some headwinds more on the wellness side. We think that's at this point, really macro probably in the lower end economic demographic households.” — Jay Mazelsky, President and Chief Executive Officer · 2026-02-02 By the August call the number was still going the wrong way: “we've continued to see declines in U.S. same-store clinical visits, 1.3% within the quarter.” — Andrew Emerson, Chief Financial Officer · 2026-08-04

It got worse. In the third quarter visits fell an estimated 1.8% — and IDEXX grew U.S. Companion Animal Diagnostics recurring revenue 9.6% anyway, a spread of roughly 1,100 basis points, the fourth consecutive quarter above that mark. The company has stopped apologising for the traffic data and started using it as a foil.

our growth, we does not rely on seeing, positive visits. We can grow irrespective of that.

That is the real change in this report. Not the headline — total revenue rose 10% year over year to about $1.2 billion in the last filed quarter — but the claim that the operating model has been decoupled from footfall. The mechanism is diagnostic utilization: more tests per visit, not more visits. Management says the majority of wellness visits still carry no blood work, which is an unusually long-duration growth lever for a company already growing double digits on a shrinking traffic base.

Promises, converted

What distinguishes this quarter from the prior four is that the deferred items arrived. Fine needle aspirate had been in a "controlled launch" since 2025 and was repeatedly pushed: “we're broadening that again meaningfully as we go into Q3 with planned full availability by the end of the year.” — Michael Erickson, President and Chief Executive Officer · 2026-08-04 It landed early. FNA is now open to every North American InVue Dx customer and bundled into every new North American placement — which converts the top of the company's own keyword list, fine needle aspirate and needle aspirate, from roadmap into revenue.

The early data is the interesting part. Customers using FNA are evaluating twice as many masses, because the glass slide and the send-out are what suppressed the test in the first place. The CEO's framing deserves quoting because it is the whole capital-allocation thesis in one sentence: “This is IDEXX innovation bending the cost curve to expand care access, and care volume.” — Michael Erickson, President and Chief Executive Officer · 2026-11-02 He then points at the addressable pool: “we can look, around the corner and see a 100 million more cytology tests being done around the world in a frankly, manual and suboptimal way.” — Michael Erickson, President and Chief Executive Officer · 2026-11-02 Nearly 11,000 InVue analyzers are installed; management says it will exceed both the 5.5 thousand placement goal for 2026 and the 20 thousand five-year target.

CancerDx runs tell a similar conversion story. Over 14,000 practices have now ordered and run the panel, and roughly 70% of runs ride along with a broader blood work panel. The number I'd watch is the competitive-lab share, which has climbed steadily across calls — 15%, then 17%, then 20%, now "nearly a quarter" of ordering customers being non-primary IDEXX reference lab accounts. Mast cell tumor detection shipped in September, pushing the panel toward roughly 40% of canine cancers once hemangiosarcoma arrives, and the price did not move. Meanwhile Catalyst ProBNP opened a cardiac category at the point of care against a field of about 24 veterinary cardiologists for tens of millions of affected pets.

The AI bet, and what it cost

The genuinely new item is software. IDEXX bought ezyVet — an AI-native ambient-listening and clinical workflow tool with roughly a $20 million annualised revenue run rate growing double digits — and folded it into the ezyVet narrative of giving clinicians back time so they can see more patients. The strategic logic is multiplier, not standalone: ambient capture of the exam-room conversation feeds the diagnostic menu and the reference lab.

The accounting is less romantic. Roughly $335 million went out the door in Q3 across the acquisition and buybacks, dilution is about $0.13 of EPS, and “we did include about 30 basis points of operating margin impact” — Andrew Emerson, Chief Financial Officer · 2026-11-02 — which is why fourth-quarter operating margin is guided down to 28.4%–29.3% against a 33.1% reported margin this quarter. Paying a software multiple for a $20 million revenue asset is only defensible if the pull-through shows up in consumables and reference lab volume. Note also what has quietly reversed: in February the answer on the corporate channel was unambiguous —

We're not placing InVue into corporate practices. As I've shared in the past. It tends to be a little bit longer sell-in cycle.

The multiple the market stopped paying

Here is the tension the tape has been pricing all year. IDXX is up 21.8% over the last 90 trading days, a clean one-way climb, and is still 12.4% below its November 2025 peak. The business is executing better than at any point in its history — gross margin of 64.0%, up 1.4 points year over year and operating margin of 35.0%, both records — while the market has spent four years compressing the price it will pay for that.

At 36.4x trailing net income, IDEXX trades near half the 74.7x it commanded in late 2021, and 9.1x revenue against a 17.6x peak. The case for owning it from here is not re-expansion but duration: cash conversion ran 110% of net income on a trailing basis, free cash flow was $421 million in the quarter, and a mid-single-digit R&D load keeps buying new menu items on installed hardware.

The contrast with the wider market is almost comic. The single loudest theme in global keyword flow right now is AI data center, which is down more than 20% over 90 days across dozens of tickers and appears nowhere in this transcript. IDEXX's AI is a stethoscope that listens and writes, not a rack of accelerators — a useful reminder that "AI" is not one trade.

What to watch: the Multi-Q Dx investor event on January 18 at VMX in Orlando, where the next point-of-care platform gets its reveal and analysts get their first real look at whether two instrument ramps can run in parallel. And the guardrail on the whole thesis — management reiterating that it is “not looking to maximize price, you know, we are really trying to expand the sector through volume.” — Michael Erickson, President and Chief Executive Officer · 2026-11-02 A company that chooses volume over price on a shrinking visit base has to be right about utilization. Three quarters of above-1,000-basis-point premiums suggest it is.